Medscape is available in 5 Language Editions – Choose your Edition here.


Neuroacanthocytosis Syndromes Clinical Presentation

  • Author: Kenneth B V Gross, MD; Chief Editor: Selim R Benbadis, MD  more...
Updated: Mar 19, 2014


The typical presentation of neuroacanthocytosis syndromes involves tic-like orofacial movements and gait instability beginning in young adulthood. In its classic form, NA is associated with orofacial tics, lingual dyskinesias, chorea, and leg buckling with ambulation. Dystonia, self-mutilating lip and tongue biting, and difficulty swallowing are also commonly seen. Occasionally, Parkinsonian features, belching, and violent truncal spasms associated with head banging can be noted.

As the disease progresses, increasing weakness and muscle wasting are often noted.

In some patients with NA, personality changes, particularly depression, appear early in the course of the disease.

Generalized tonic-clonic seizures and complex partial seizures have been reported.[19] The latter seizure type has featured déjà vu phenomena.

In the variant syndromes, the patient may present with gait imbalance as a prominent neurological symptom due to involvement of spinocerebellar pathways.

Some patients with variant syndromes may present with progressive dyspnea due to cardiomyopathy.

Some patients exhibit Tourettelike tics, which are thought to be due to hypersensitivity of dopamine receptors. As the disease progresses, the dopamine receptors may become hyporesponsive or decrease in number sufficiently to result in a parkinsonian syndrome.

Progressive cognitive disturbance is often a part of the symptomatic decline in NA syndromes.


Diagnostic Considerations

Although chorea, reduced/absent reflexes, and acanthocytosis are extremely common in NA syndromes, all 3 of these signs may not be present in every patient with NA.

Features including orofacial tics, seizures, neuropsychiatric abnormalities, dysphagia, dysarthria, elevated CPK levels, and proximal muscle weakness and wasting are noted in varying combinations in a majority of the patients.

Occasional patients simply have acanthocytosis combined with one or more of the following:

  • Chorea/dyskinesia
  • Amyotrophy
  • CPK elevation
  • Parkinsonism or ataxia (rare)

Gilles de la Tourette syndrome

Orofacial tics are noted in both disorders, but acanthocytosis, high CPK level, and amyotrophy are not present in Tourette syndrome.

Huntington disease (HD)

In HD, limb chorea is more prominent and tics usually are not present. Early dementia commonly is associated with HD and not NA. No acanthocytosis or amyotrophy is noted in HD. The autosomal dominant pattern of inheritance in HD is helpful in making this diagnosis. Currently, definitive genetic testing for HD is available.

Hallervorden-Spatz disease (HS)

The classic basal ganglia iron distribution in the globus pallidus seen in HS usually is not seen in NA syndromes. In a young patient with HS, a syndrome of acanthocytosis, retinitis pigmentosa, low betalipoproteins, and a movement disorder that is consistent with NA has been described.

Wilson disease (WD)

Copper abnormalities or Kayser-Fleisher rings noted in WD do not occur in NA. The movement disorder in WD usually presents at a younger age (children or adolescents).

Polymyositis (PM)

Although patients with PM can show a high CPK level, an extrapyramidal system movement disorder is not part of the spectrum of PM. Both PM and NA can have a hemolytic anemia, the latter due to acanthocytosis. Acanthocytosis is not present in PM.

Bassen-Kornzweig syndrome (BK)

Abetalipoproteinemia, ataxia, and retinitis pigmentosa typically are seen in a child with acanthocytosis. Occasional NA syndromes have been reported in children, although these do not have all the BK features other than the acanthocytosis and decreased betalipoproteins.

McLeod syndrome

Acanthocytosis and high CPK level due to a benign skeletal myopathy can at times be complicated by a cardiomyopathy, involuntary movements, and/or dementia. This syndrome, found in children and adults with the Kell-null phenotype, is actually part of the NA variant syndrome family. Psychosis has also been described as a presenting feature.

Chorea-amyotrophy with chronic hemolytic anemia

This syndrome also has been described to include NA type dyskinesia. Lack of acanthocytosis and nonpallidal basal ganglia iron deposition distinguishes chorea-amyotrophy with chronic hemolytic anemia from HS.

Chorea-acanthocytosis presenting as motor neuron disease

As suggested by several researchers, including separate investigations by Bird and Gross, the amyotrophy of NA implicates features of motor neuron disease.[20, 21]

A recent report[22] cited a patient with a gait disturbance and dysarthria, with clinical and neurophysiological assessment disclosing upper and lower motor neuron signs suggestive of motor neuron disease. Involuntary movements were not present initially but later were observed. A novel mutation of chorein and acanthocytes were identified.

This is also extremely interesting in view of the identification of motor neuron disease, ie, amyotrophic lateral sclerosis plus frontotemporal dementia in the same patients[23] and related to a gene defect on chromosome 9, not far removed from the gene abnormality in NA. It would be worthwhile to check for morphologic red blood cell disorders in these patients in this regard and in view of the various links to red blood cell abnormalities in patients with degenerative disease of the nervous system.

MELAS syndrome

Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes in children (MELAS) have been reported with acanthocytosis.



In patients with classic NA, multiple physical findings are observed.

Ticlike facial movements are noted in the context of tongue mutilation and dysarthric speech. Carbamazepine-sensitive paroxysmal kinesigenic dyskinesia and tongue protrusion dystonia have also been reported.

Truncal chorea can explain gait imbalance. However, gait ataxia can be explained on a cerebellar or spinocerebellar basis.

Classically, distal muscle wasting often is noted in the context of hand atrophy and a pes cavus deformity.

In variant syndromes, these features need not be present. In some variant cases, the patient eventually will be wheelchair bound because of both the chorea and the muscle wasting.

Cogwheel rigidity, resting tremor, and bradykinesia are late physical findings in patients with NA who have a parkinsonian syndrome.

Organic mental syndromes are common, including anxiety, depression, psychomotor agitation, obsessive-compulsive thinking, psychosis, paranoia, schizophrenialike features[24, 25] , cognitive dysfunction, and hallucinations.

Retinitis pigmentosa has been described in the HS variant of NA.

Generally, the acanthocytosis does not produce clinical symptoms or physical findings. In one NA variant syndrome, however, a child presented with acanthocytosis-related hemolytic anemia that included malaise and splenomegaly. Another variant case included attacks of jaundice that may have been related to the hemolysis.

Acanthocytosis (though not necessarily that related to NA) may be a predisposing factor for nonketotic hyperglycemia-induced chorea-ballism.



NA syndromes can be related to, if not caused by, specific gene defects.

The gene defects may induce hypobetalipoproteinemia.

Since most patients with NA do not have abnormalities in betalipoproteins, the role of hypobetalipoproteinemia in the pathophysiology of NA syndromes is still in question.

Similarly, although membrane protein and ganglioside abnormalities have been noted in some patients with an NA syndrome, and others have serum antibodies against cell membrane components and evidence of sialic acid residues usually noted in active inflammation, none of these findings are known to be clearly causative of the disease in NA syndrome.

NA has been associated with a defect of the 4.1R membrane protein in erythrocytes. This might reflect the expression pattern in the central nervous system, especially the basal ganglia and might lead to dysfunction of AMPA-mediated glutamate transmission.

Contributor Information and Disclosures

Kenneth B V Gross, MD Founder, Owner, Fusion Clinical Multimedia, Inc, Division of Neurology, Fusion Clinical Multimedia Educational Center

Kenneth B V Gross, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.


Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics; Eisai; Glaxo Smith Kline; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics; Lundbeck; Sepracor; Sunovion; UCB; Upsher-Smith.

Additional Contributors

Roberta J Seidman, MD Associate Professor of Clinical Pathology, Stony Brook University; Director of Neuropathology, Department of Pathology, Stony Brook University Medical Center

Roberta J Seidman, MD is a member of the following medical societies: American Academy of Neurology, Suffolk County Society of Pathologists, New York Association of Neuropathologists (The Neuroplex), American Association of Neuropathologists

Disclosure: Nothing to disclose.

  1. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol. 1968 Oct. 19(4):403-9. [Medline].

  2. Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol. 1968 Feb. 18(2):134-40. [Medline].

  3. Walker RH. Autosomal-dominant chorea-acanthocytosis: Report of a family and neuropathology In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  4. Walker RH, Schulz VP, Tikhonova IR, Mahajan MC, Mane S, Arroyo Muniz M. Genetic diagnosis of neuroacanthocytosis disorders using exome sequencing. Mov Disord. 2011 Oct 28. [Medline].

  5. Redman CM, Reid ME. The McLeod syndrome: an example of the value of integrating clinical and molecular studies. Transfusion. 2002 Mar. 42(3):284-6. [Medline].

  6. van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol. 2000 Mar. 60(4):385-405. [Medline].

  7. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol. 2001 Mar. 49(3):384-92. [Medline].

  8. Wiethoff S, Xiromerisiou G, Bettencourt C, Kioumi A, Tsiptsios I, Tychalas A. Novel single base-pair deletion in exon 1 of XK gene leading to McLeod syndrome with chorea, muscle wasting, peripheral neuropathy, acanthocytosis and haemolysis. J Neurol Sci. 2014 Feb 1. [Medline].

  9. Bosman GM. Erythrocyte membrane abnormalities in neuroacanthocytosis: Evidence for a neuron-erythrocyte axis?. Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

  10. De Franceschi L, Corrocher R. Erythrocyte membrane anion exchange abnormalities in chorea-acanthocytosis: The band 3 network. Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  11. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol. 2004 Aug. 56(2):299-302. [Medline].

  12. Bayreuther C, Borg M, Ferrero-Vacher C, Chaussenot A, Lebrun C. [Chorea-acanthocytosis without acanthocytes]. Rev Neurol (Paris). 2010 Jan. 166(1):100-3. [Medline].

  13. Walker RH, Danek A, Uttner I, Offner R, Reid M, Lee S. McLeod phenotype without the McLeod syndrome. Transfusion. 2007 Feb. 47(2):299-305. [Medline].

  14. De Franceschi L, Tomelleri C, Matte A, Brunati AM, Bovee-Geurts PH, Bertoldi M. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood. 2011 Nov 17. 118(20):5652-63. [Medline].

  15. De Franceschi L, Scardoni G, Tomelleri C, Danek A, Walker RH, Jung HH. Computational identification of phospho-tyrosine sub-networks related to acanthocyte generation in neuroacanthocytosis. PLoS One. 2012. 7(2):e31015. [Medline].

  16. Kanjanasut N, Jagota P, Bhidayasiri R. The first case report of neuroacanthocytosis in Thailand: utilization of a peripheral blood smear technique for detecting acanthocytes. Clin Neurol Neurosurg. 2010 Jul. 112(6):541-3. [Medline].

  17. Man BL, Yuen YP, Yip SF, Ng SH. The first case report of McLeod syndrome in a Chinese patient. BMJ Case Rep. 2013. 2013:[Medline].

  18. Chakravarty A, Bhattacharya P, Banerjee D, Mukherjee S. Mcleod syndrome: Report of an Indian family with phenotypic heterogeneity. Ann Indian Acad Neurol. 2011 Jan. 14(1):53-5. [Medline]. [Full Text].

  19. Troiano AR, Trevisol-Bittencourt PC. [Neuroacanthocytosis. A case report]. Arq Neuropsiquiatr. 1999 Jun. 57(2B):489-94. [Medline].

  20. Bird TD, Cederbaum S, Valey RW, Stahl WL. Familial degeneration of the basal ganglia with acanthocytosis: a clinical, neuropathological, and neurochemical study. Ann Neurol. 1978 Mar. 3(3):253-8. [Medline].

  21. Gross KB, Skrivanek JA, Carlson KC, Kaufman DM. Familial amyotrophic chorea with acanthocytosis. New clinical and laboratory investigations. Arch Neurol. 1985 Aug. 42(8):753-6. [Medline].

  22. Neutel D, Miltenberger-Miltenyi G, Silva I, de Carvalho M. Chorea-acanthocytosis presenting as motor neuron disease. Muscle Nerve. 2012 Feb. 45(2):293-5. [Medline].

  23. Orr HT. FTD and ALS: genetic ties that bind. Neuron. 2011 Oct 20. 72(2):189-90. [Medline].

  24. Jung HH, Haker H. Schizophrenia as a manifestation of X-linked Mcleod-Neuroacanthocytosis syndrome. J Clin Psychiatry. 2004 May. 65(5):722-3. [Medline].

  25. Bruneau MA, Lespérance P, Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci. 2003. 15(3):378-80. [Medline].

  26. Dotti MT, Battisti C, Malandrini A, et al. McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. Mov Disord. 2000 Nov. 15(6):1282-4. [Medline].

  27. Nicholl DJ, Sutton I, Dotti MT, Supple SG, Danek A, Lawden M. White matter abnormalities on MRI in neuroacanthocytosis. J Neurol Neurosurg Psychiatry. 2004 Aug. 75(8):1200-1. [Medline].

  28. Gradstein L, Danek A, Grafman J, Fitzgibbon EJ. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci. 2005 Jun. 46(6):1979-87. [Medline].

  29. Volkmann J. Is surgical treatment an option for chorea-acanthocytosis? In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

  30. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord. 2005. 20:1681-1682.

  31. Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc Natl Acad Sci U S A. 2001 Jan 2. 98(1):3-4. [Medline].

  32. Robinson D, Smith M, Reddy R. Neuroacanthocytosis. Am J Psychiatry. 2004 Sep. 161(9):1716. [Medline].

  33. Habermeyer B, Fuhr P. Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram. Pharmacopsychiatry. 2007 Mar. 40(2):87. [Medline].

  34. Vázquez MJ, Martínez MC. Electroconvulsive Therapy in Neuroacanthocytosis or McLeod Syndrome. J ECT. 2008 Nov 7. [Medline].

  35. Akamatsu K, Sakaue H, Tada K, et al. A case report of abetalipoproteinemia (Bassen-Kornzweig syndrome)--the first case in Japan. Jpn J Med. 1983 Aug. 22(3):231-6. [Medline].

  36. Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia. 2005 Aug. 46(8):1256-63. [Medline].

  37. Alonso ME, Teixeira F, Jimenez G, Escobar A. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci. 1989 Nov. 16(4):426-31. [Medline].

  38. Andermann E, Jansen A, Andermann F. French-Canadian chorea-acanthocytosis. Mov Disord. 2005. 20:1678.

  39. Arimura H, Kuriyama M, Higuchi I, et al. [Paroxysmal dystonic choreoathetosis with chronic hemolytic anemia and morphologically abnormal erythrocytes]. Rinsho Shinkeigaku. 1995 Jan. 35(1):29-33. [Medline].

  40. Bansal I, Jeon HR, Hui SR, Calhoun BW, Manning DW, Kelly TJ. Transfusion support for a patient with McLeod phenotype without chronic granulomatous disease and with antibodies to Kx and Km. Vox Sang. 2008 Apr. 94(3):216-20. [Medline].

  41. Beal MF. In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

  42. Bharucha EP, Bharucha NE. Choreo-acanthocytosis. J Neurol Sci. 1989 Feb. 89(2-3):135-9. [Medline].

  43. Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. Mov Disord. 2000 Nov. 15(6):1271-3. [Medline].

  44. Bramanti P, Ricci RM, Candela L, et al. Sleep spindles in amyotrophic chorea-acanthocytosis disease. Acta Neurol (Napoli). 1987 Jun. 9(3):191-8. [Medline].

  45. Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord. 2002 Jan. 17(1):204-7. [Medline].

  46. Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor thalamus in a case of chorea-acanthocytosis. Neurology. 2002 Dec 24. 59(12):1982-4. [Medline].

  47. Cavalli G, de Gregorio C, Nicosia S, et al. [Cardiac involvement in familial amytrophic chorea with acantocytosis: description of two new clinical cases]. Ann Ital Med Int. 1995 Oct-Dec. 10(4):249-52. [Medline].

  48. Chorea-acanthocytosis: report of two Brazilian cases.

  49. Clapéron A, Hattab C, Armand V, Trottier S, Bertrand O, Ouimet T. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res. 2007 May 25. 1147:12-24. [Medline].

  50. Danek A, Dobson-Stone C, Velayos-Baeza A. The phenotype of chorea-acanthocytosis: a review of 106 patients with VPS13A mutations. Mov Disord. 2005. 20:1678.

  51. Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci. 2005 Mar 15. 229-230:171-86. [Medline].

  52. Danek A, Uttner I, Vogl T, et al. Cerebral involvement in McLeod syndrome. Neurology. 1994 Jan. 44(1):117-20. [Medline].

  53. Dobson-Stone C. The spectrum of mutations and possible function of the CHAC gene In: Danek A, ed. Neuoracanthocytosis Syndromes. Springer. 2005.

  54. Faillace RT, Kingston WJ, Nanda NC, Griggs RC. Cardiomyopathy associated with the syndrome of amyotrophic chorea and acanthocytosis. Ann Intern Med. 1982 May. 96(5):616-7. [Medline].

  55. Ferrer X, Julien J, Vital C, et al. [Choreo-acanthocytosis]. Rev Neurol (Paris). 1990. 146(12):739-45. [Medline].

  56. Gil-Nagel A, Morlan L, Balseiro J, et al. [Neuro-acanthocytosis with associated myopathy. A case report]. Neurologia. 1994 Apr. 9(4):165-8. [Medline].

  57. Gross KB, Skrivanek JA, Emeson EE. Ganglioside abnormality in amyotrophic chorea with acanthocytosis. Lancet. 1982 Oct 2. 2(8301):772. [Medline].

  58. Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci. 1995 Dec. 134 Suppl:84-91. [Medline].

  59. Hardie RJ. Acanthocytosis and neurological impairment--a review. Q J Med. 1989 Apr. 71(264):291-306. [Medline].

  60. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991 Feb. 114 ( Pt 1A):13-49. [Medline].

  61. Hashimoto T, Nakadai A, Fujimori N, Yanagisawa N. [A case of "chorea with acanthocytosis and neuropathy" (chorea-acanthocytosis) with parkinsonism without areflexia]. Rinsho Shinkeigaku. 1987 Jan. 27(1):88-93. [Medline].

  62. Hewer E, Danek A, Schoser BG, Miranda M, Reichard R, Castiglioni C. McLeod myopathy revisited: more neurogenic and less benign. Brain. 2007 Dec. 130(Pt 12):3285-96. [Medline].

  63. Higgins JJ, Patterson MC, Papadopoulos NM, et al. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology. 1992 Jan. 42(1):194-8. [Medline].

  64. Hirayama M, Hamano T, Shiratori M, et al. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1. J Neurol Sci. 1997 Oct 3. 151(1):23-4. [Medline].

  65. Iwata M, Fuse S, Sakuta M, Toyokura Y. Neuropathological study of chorea-acanthocytosis. Jpn J Med. 1984 May. 23(2):118-22. [Medline].

  66. Katsube T, Shimono T, Ashikaga R, Hosono M, Kitagaki H, Murakami T. Demonstration of Cerebellar Atrophy in Neuroacanthocytosis of 2 Siblings. AJNR Am J Neuroradiol. 2008 Oct 22. [Medline].

  67. Kohler B. [Hallervorden-Spatz syndrome with acanthocytosis]. Monatsschr Kinderheilkd. 1989 Sep. 137(9):616-9. [Medline].

  68. Kurano Y, Nakamura M, Ichiba M, Matsuda M, Mizuno E, Kato M. Chorein deficiency leads to upregulation of gephyrin and GABA(A) receptor. Biochem Biophys Res Commun. 2006 Dec 15. 351(2):438-42. [Medline].

  69. Kuroiwa Y, Ohnishi A, Sato Y, Kanazawa I. Chorea acanthocytosis: clinical pathological and biochemical aspects. Int J Neurol. 1984. 18:64-74. [Medline].

  70. Kutcher JS, Kahn MJ, Andersson HC, Foundas AL. Neuroacanthocytosis masquerading as Huntington's disease: CT/MRI findings. J Neuroimaging. 1999 Jul. 9(3):187-9. [Medline].

  71. Larget-Piet L, Pouplard F. [Ataxia-areflexia-familial steatorrhea without abetalipoproteinemia or acanthocytosis]. J Genet Hum. 1981 Sep. 29(3):249-51. [Medline].

  72. Limos LC, Ohnishi A, Sakai T, et al. "Myopathic" changes in chorea-acanthocytosis. Clinical and histopathological studies. J Neurol Sci. 1982 Jul. 55(1):49-58. [Medline].

  73. Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan. 2006 Mar. 15(1):38-42. [Medline].

  74. Luckenbach MW, Green WR, Miller NR, et al. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol. 1983 Mar. 95(3):369-82. [Medline].

  75. Lupo I, Aragona F, Fierro B, et al. Choreo-acanthocytosis with myopathy. Report of a case. Acta Neurol (Napoli). 1987 Oct-Dec. 9(5-6):334-8. [Medline].

  76. Malandrini A, Fabrizi GM, Truschi F, et al. Atypical McLeod syndrome manifested as X-linked chorea-acanthocytosis, neuromyopathy and dilated cardiomyopathy: report of a family. J Neurol Sci. 1994 Jun. 124(1):89-94. [Medline].

  77. Marson AM, Bucciantini E, Gentile E, Geda C. Neuroacanthocytosis: clinical, radiological, and neurophysiological findings in an Italian family. Neurol Sci. 2003 Oct. 24(3):188-9. [Medline].

  78. Miranda M, Campero M, Tenhamm E, Villagra R. [Neuroacanthocytosis: report of 3 cases]. Rev Med Chil. 1993 Feb. 121(2):176-9. [Medline].

  79. Miranda M, Castiglioni C, Frey BM, Hergersberg M, Danek A, Jung HH. Phenotypic variability of a distinct deletion in McLeod syndrome. Mov Disord. 2007 Jul 15. 22(9):1358-61. [Medline].

  80. Mukoyama M, Kazui H, Sunohara N, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol. 1986 Aug. 233(4):228-32. [Medline].

  81. Müller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol. 2007 Aug. 254(8):1081-8. [Medline].

  82. Nielsen SM, Temlett JA. Neuro-acanthocytosis--a rare cause of chorea. S Afr Med J. 1997 Jul. 87(7):897-8. [Medline].

  83. Nihashi H, Yoshida M. [Cognitive function in patients with parkinsonism--in relationship with frontal lobe symptoms]. No To Shinkei. 1988 Mar. 40(3):261-6. [Medline].

  84. Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol. 2007 Nov 26. [Medline].

  85. Oechsner M, Buchert R, Beyer W, Danek A. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry. 2001 Apr. 70(4):517-20. [Medline]. [Full Text].

  86. Ogawa T, Seki H, Okita N, et al. [A case of chorea-acanthocytosis associated with low glycohemoglobin A1c]. Rinsho Shinkeigaku. 1993 Mar. 33(3):344-6. [Medline].

  87. Ohnishi A, Sato Y, Nagara H, et al. Neurogenic muscular atrophy and low density of large myelinated fibres of sural nerve in chorea-acanthocytosis. J Neurol Neurosurg Psychiatry. 1981 Jul. 44(7):645-8. [Medline].

  88. Orlacchio A, Calabresi P, Rum A, Tarzia A, Salvati AM, Kawarai T, et al. Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurol. 2007 Feb 13. 7:4. [Medline].

  89. Orrell RW, Amrolia PJ, Heald A, et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology. 1995 Mar. 45(3 Pt 1):487-92. [Medline].

  90. Parhofer KG, Richter WO, Stiess W, Schwandt P. [Acanthocytosis, short stature and disordered deep sensation in a 26-year-old patient]. Internist (Berl). 1989 Jun. 30(6):382-5. [Medline].

  91. Pisani A, Diomedi M, Rum A, Cianciulli P, Floris R, Orlacchio A, et al. Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. J Neurol Neurosurg Psychiatry. 2005 Dec. 76(12):1717-9. [Medline].

  92. Rubio JP, Danek A, Stone C, et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet. 1997 Oct. 61(4):899-908. [Medline].

  93. Ruiz-Sandoval JL, García-Navarro V, Chiquete E, Dobson-Stone C, Monaco AP, Alvarez-Palazuelos LE, et al. Choreoacanthocytosis in a Mexican family. Arch Neurol. 2007 Nov. 64(11):1661-4. [Medline].

  94. Saggese G, Baroncelli GI, Bertelloni S, et al. [Chronic granulomatous disease and McLeod phenotype. Description of a case]. Minerva Pediatr. 1990 Apr. 42(4):151-6. [Medline].

  95. Saiki S, Sakai K, Murata KY, Saiki M, Nakanishi M, Kitagawa Y, et al. Primary skeletal muscle involvement in chorea-acanthocytosis. Mov Disord. 2007 Apr 30. 22(6):848-52. [Medline].

  96. Sano A. [Hereditary chorea--update]. Rinsho Shinkeigaku. 2004 Nov. 44(11):932-4. [Medline].

  97. Scheid R, Bader B, Ott DV, Merkenschlager A, Danek A. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology. 2009 Oct 27. 73(17):1419-22. [Medline].

  98. Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, Limousin P. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology. 2006 Sep 26. 67(6):940-3. [Medline].

  99. Senda Y, Koike Y, Sugimura K, et al. [Chorea-acanthocytosis with catecholamine abnormality and orthostatic hypotension--a case report]. Rinsho Shinkeigaku. 1987 Jul. 27(7):898-903. [Medline].

  100. Serra S, Arena A, Xerra A, et al. Amyotrophic choreoacanthocytosis: is it really a very rare disease?. Ital J Neurol Sci. 1986 Oct. 7(5):521-4. [Medline].

  101. Serra S, Xerra A, Arena A. Amyotrophic choreo-acanthocytosis: a new observation in southern Europe. Acta Neurol Scand. 1986 May. 73(5):481-6. [Medline].

  102. Shah JR, Patkar DP, Kamat RN. A case of McLeod phenotype of neuroacanthocytosis brain MR features and literature review. Neuroradiol J. 2013 Feb. 26(1):21-6. [Medline].

  103. Sobue G, Mukai E, Fujii K, et al. Peripheral nerve involvement in familial chorea-acanthocytosis. J Neurol Sci. 1986 Dec. 76(2-3):347-56. [Medline].

  104. Sotaniemi KA. Chorea-acanthocytosis. Neurological disease with acanthocytosis. Acta Neurol Scand. 1983 Jul. 68(1):53-6. [Medline].

  105. Spencer SE, Walker FO, Moore SA. Chorea-amyotrophy with chronic hemolytic anemia: a variant of chorea-amyotrophy with acanthocytosis. Neurology. 1987 Apr. 37(4):645-9. [Medline].

  106. Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985 Mar. 35(3):366-70. [Medline].

  107. Sugihara R, Ueyama H, Fujimoto S, et al. [A case of McLeod syndrome]. Rinsho Shinkeigaku. 1998 Oct-Nov. 38(10-11):915-9. [Medline].

  108. Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain. 1983 Sep. 106 (Pt 3):717-33. [Medline].

  109. Takahashi Y, Kojima T, Atsumi Y, et al. [Case of chorea-acanthocytosis with various psychotic symptoms]. Seishin Shinkeigaku Zasshi. 1983. 85(8):457-72. [Medline].

  110. Takashima H, Sakai T, Iwashita H, et al. A family of McLeod syndrome, masquerading as chorea-acanthocytosis. J Neurol Sci. 1994 Jun. 124(1):56-60. [Medline].

  111. Terao S, Sobue G, Takahashi M, et al. [Disturbance of hypothalamic-pituitary hormone secretion in familial chorea-acanthocytosis]. No To Shinkei. 1995 Jan. 47(1):57-61. [Medline].

  112. Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

  113. Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

  114. Tsai CH, Chen RS, Chang HC, et al. Acanthocytosis and spinocerebellar degeneration: a new association?. Mov Disord. 1997 May. 12(3):456-9. [Medline].

  115. Tschopp L, Raina G, Salazar Z, Micheli F. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord. 2008. 14(5):440-2. [Medline].

  116. Villegas A, Moscat J, Vazquez A, et al. A new family with hereditary choreo-acanthocytosis. Acta Haematol. 1987. 77(4):215-9. [Medline].

  117. Walker RH, Danek A, Dobson-Stone C, et al. Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes. Mov Disord. 2006 Nov. 21(11):1794-805. [Medline].

  118. Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. 2007 Nov. 7(6):360-73. [Medline].

  119. Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol. 1992 Jul. 239(6):302-6. [Medline].

  120. Woodruff RK, Wiley JS, Bell WR, et al. Acanthocytosis and haemolytic anaemia due to the McLeod blood group. Aust N Z J Med. 1981 Apr. 11(2):184-7. [Medline].

  121. Zyskowski LP, Bunch TW, Hoagland HC, et al. Mcleod syndrome (hemolysis, acanthocytosis, and increased serum creatine kinase): potential confusion with polymyositis. Arthritis Rheum. 1983 Jun. 26(6):806-8. [Medline].

Patient with choreoacanthocytosis. A: Note self-mutilation of the lips owing to orofacial dyskinesia. B: Peripheral blood smear exhibits acanthocytes (Wright-Giemsa, original magnification, >100). C: Coronal view of T1-weighted MRI shows atrophy of the caudate nuclei. Archives of Neurology 64(11):1661-1664 2007 Copyright © 2010 American Medical Association.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.